Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VS-7375 in advanced KRAS G12D-mutant solid tumors
2025-523432-39-01Phase 2Authorised
- Sponsor
- Verastem Oncology
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of GFH375 in Nonhematologic neoplasms, pancreatic adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) and 1 more (10 arms), sponsored by Verastem Oncology. Primary endpoints: Safety and tolerability, Dose-limiting toxicities during DLT period and 3 more. Planned start Sep 2026; status: authorised.
02
Drugs
GFH375
03
Conditions
Nonhematologic neoplasmspancreatic adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)colorectal adenocarcinoma
Beyond the preview
Go deeper on 2025-523432-39-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523432-39-01.